Abbvie Inc
Change company Symbol lookup
Select an option...
ABBV Abbvie Inc
AXS AXIS Capital Holdings Ltd
SPNS Sapiens International Corporation NV
SPCE Virgin Galactic Holdings Inc
BBLG Bone Biologics Corp
RPT RPT Realty
CLM Cornerstone Strategic Value Fund
RCI Rogers Communications Inc
ADRA Adara Acquisition Corp
EVTC Evertec Inc
Go

Health Care : Biotechnology | Large Cap Value
Company profile

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products include Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.

Closing Price
$140.25
Day's Change
-0.09 (-0.06%)
Bid
--
Ask
--
B/A Size
--
Day's High
142.24
Day's Low
139.88
Volume
(Light)
Volume:
3,819,828

10-day average volume:
6,683,311
3,819,828

Company Profile

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products include Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.

Valuation Ratios

Price/Earnings (TTM)
19.52x
Price/Sales (TTM)
4.25x
Price/Book (MRQ)
16.66x
Price/Cash Flow (TTM)
11.67x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend

Short Interest

July 2022
Current Month
14.0M
Previous Month
14.4M
Percent of Float
0.79%
Days to Cover
2.6326 Days

Share Information

ABBV is in a share class of common stock
Float
1.8B
Shares Outstanding
1.8B
Institutions Holding Shares
3,669
68.63%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Richard A. GonzalezChmn.
  • Robert A. MichaelPres.
  • Laura J. Schumacher
  • Scott T. ReentsCFO
  • Timothy J. Richmond

Address

Insider Trading

During the most recent quarter, 959K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.